Collaborative Partnership Designed to Enhance
Nationwide Efforts to Combat the Opioid Epidemic and Improve
Addiction Recovery
Masimo (NASDAQ: MASI), a leading global medical technology
innovator, today announced that it is partnering with Mobilize
Recovery, a nonprofit organization dedicated to ending America’s
addiction and overdose crisis, by sponsoring and joining the
Mobilize Recovery 2024 bus tour. The tour, which kicks off on
September 20th in Los Angeles, with the first stop in Irvine, at
the Masimo headquarters, is set to travel to 15 key cities around
the U.S. to raise awareness, educate, and support communities
around the country as they seek to prevent overdose and make
sustainable improvements in addiction recovery outcomes. As part of
this sixth annual initiative, Mobilize Recovery and Masimo will be
showcasing two key Masimo innovations, Opioid Halo™ and Bridge™,
which are designed to help people who are using opioids stay safe
and reduce withdrawal symptoms during addiction recovery,
respectively.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240605557264/en/
Mobilize Recovery and Masimo Bridge™ and
Opioid Halo™ (Graphic: Business Wire)
Founded by Mr. Ryan Hampton, Mobilize Recovery brings together
recovery advocates, nonprofit organizations, allies, business
leaders and innovators like Masimo, government partners, and
like-minded community-based organizations with an interest in
creating sustainable change and community solutions, as well as
celebrating recovery from substance abuse disorder and mental
health challenges. Engaging year-round with mobilizers, Mobilize
Recovery provides partnership support and education to uplift and
sustain partners’ work; help them develop action-oriented,
measurable, scalable goals; raise public awareness; and prevent
overdose.
Ryan Hampton, Founder and Executive Director of Mobilize
Recovery, said, “Mobilize Recovery champions a grassroots approach,
empowering advocates, innovators, businesses, and communities
battling the overdose crisis firsthand. We see Masimo as a leading
innovation partner in the recovery movement, uniquely positioned to
drive technological advancements that make a real impact. We're
thrilled to collaborate with a company so committed to leveraging
technology for groundbreaking solutions in recovery. Masimo's
Opioid Halo and Bridge have shown immense promise in helping opioid
users, and we're eager to see their full potential realized. In
Masimo’s CEO, Joe Kiani, we've found a passionate voice advocating
for overcoming this epidemic, a true thought leader in the recovery
field with an unwavering dedication to making a difference.”
Joe Kiani, Founder and CEO of Masimo, added, “We are excited to
sponsor Mobilize Recovery, partner with their amazing team, and
help kick off the bus tour in September. Masimo is committed to
creating evidence-based solutions that fill in existing gaps in
patient support networks. We were honored to be chosen by the FDA
as a winner of their FDA Opioid Innovation Challenge for our
solution to help prevent opioid overdose. With Opioid Halo, we
became the first winner to have an authorized device to address the
crisis. Bridge, in turn, is the first FDA-cleared medical device to
help in the reduction of opioid withdrawal symptoms. Together, we
believe these products, and the amazing efforts of Mobilize
Recovery and its partners, can make a real difference in fighting
the opioid crisis – as well as help eliminate the stigma around
addiction.”
Opioid Halo, an opioid overdose prevention and alert system, was
granted a De Novo by the FDA in 2023, making it the first and only
FDA-cleared monitoring solution for detecting opioid-induced
respiratory depression (OIRD). Opioid Halo advances the forefront
of continuous monitoring through its unique Opioid Halo engine, an
advanced pattern recognition algorithm which helps detect and
quantify the risk of severe OIRD. Combined with its innovative
distributed architecture, Opioid Halo helps to manage and send
escalating alarms to family members, friends, and caregivers,
notifying them that help may be needed due to an opioid overdose –
including triggering an automatic wellness call, which may lead to
EMS being dispatched.
Bridge, a drug-free opioid withdrawal device, uses
neuromodulation to aid in the reduction of symptoms associated with
opioid withdrawal. Bridge, which has also been granted a De Novo by
the FDA, is the first evidence-based, drug-free, non-surgical
device of its kind. While medication-assisted treatment can be
effective in helping treat opioid withdrawal symptoms, Bridge may
help significantly reduce those symptoms, within 30 minutes,
helping users make progress in their treatment by bridging the gap
on the road to recovery. Bridge fits behind the ear – applied by a
healthcare provider in a short, non-surgical procedure – and works
by sending electrical impulses to the nerves around the ear, which
transmit them to the brain, providing up to five days of continuous
relief from withdrawal symptoms.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.1
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,2 improve CCHD screening in
newborns,3 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.4-7 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,8 and is
the primary pulse oximetry at 9 of the top 10 hospitals as ranked
in the 2022-23 U.S. News and World Report Best Hospitals Honor
Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7®,
Radius PPG®, and Radius VSM™, portable devices like Rad-67®,
fingertip pulse oximeters like MightySat® Rx, and devices available
for use both in the hospital and at home, such as Rad-97® and the
Masimo W1® Medical Watch. Masimo hospital and home automation and
connectivity solutions are centered around the Masimo Hospital
Automation™ platform, and include Iris® Gateway, iSirona™, Patient
SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo
SafetyNet®. Its growing portfolio of health and wellness solutions
includes Radius Tº® and Masimo W1 Sport. Additional information
about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo Opioid Halo™ and
Bridge™, as well as the potential benefits of Masimo’s partnership
with Mobilize Recovery. These forward-looking statements are based
on current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Opioid Halo and Bridge, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240605557264/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024